ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
ProMIS Neurosciences (Nasdaq: PMN), a clinical-stage biotechnology company, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. The company's CEO, Neil Warma, will engage in a fireside chat on Wednesday, February 5, 2025, at 1:30 p.m. ET in New York.
ProMIS specializes in developing antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, including Alzheimer's disease, ALS, and multiple system atrophy. The fireside chat will be accessible via live webcast through the Events page on the company's website and will remain available for at least 30 days after the event.
ProMIS Neurosciences (Nasdaq: PMN), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione al prossimo Guggenheim Securities SMID Cap Biotech Conference. Il CEO dell'azienda, Neil Warma, parteciperà a una conversazione informale mercoledì 5 febbraio 2025, alle 13:30 ET a New York.
ProMIS si specializza nello sviluppo di terapie anticorpali mirate a proteine mal ripiegate tossiche nelle malattie neurodegenerative, tra cui la malattia di Alzheimer, la SLA e l'atrofia sistemica multipla. La conversazione informale sarà accessibile tramite una web broadcast in diretta attraverso la pagina Eventi sul sito web dell'azienda e rimarrà disponibile per almeno 30 giorni dopo l'evento.
ProMIS Neurosciences (Nasdaq: PMN), una compañía de biotecnología en etapa clínica, ha anunciado su participación en la próxima Conferencia de Biotecnología SMID Cap de Guggenheim Securities. El CEO de la compañía, Neil Warma, participará en una charla informal el miércoles 5 de febrero de 2025, a la 1:30 p.m. ET en Nueva York.
ProMIS se especializa en desarrollar terapias con anticuerpos dirigidas a proteínas mal plegadas y tóxicas en enfermedades neurodegenerativas, incluyendo la enfermedad de Alzheimer, ELA y atrofia sistémica múltiple. La charla informal estará disponible a través de una transmisión en vivo por el sitio web de la compañía y permanecerá accesible durante al menos 30 días después del evento.
ProMIS Neurosciences (Nasdaq: PMN), 임상 단계의 생명공학 회사,가 다가오는 Guggenheim Securities SMID Cap Biotech Conference에 참여한다고 발표했습니다. 회사의 CEO인 Neil Warma는 2025년 2월 5일 수요일, 오후 1:30 ET에 뉴욕에서 진행되는 대화형 행사에 참석할 예정입니다.
ProMIS는 알츠하이머병, ALS, 다계통 위축증 등 신경퇴행성 질환에서 독성 변형 단백질을 겨냥한 항체 치료제를 개발하는 데 전문화되어 있습니다. 이 대화형 행사는 회사 웹사이트의 이벤트 페이지를 통해 실시간 웹캐스트로 접근 가능하며, 행사 후 최소 30일 동안 이용할 수 있습니다.
ProMIS Neurosciences (Nasdaq: PMN), une entreprise de biotechnologie en phase clinique, a annoncé sa participation à la prochaine Conférence sur les Biotechs de la SMID Cap de Guggenheim Securities. Le PDG de l'entreprise, Neil Warma, participera à une discussion informelle mercredi 5 février 2025, à 13h30 ET à New York.
ProMIS se spécialise dans le développement de thérapies par anticorps ciblant des protéines mal repliées et toxiques dans les maladies neurodégénératives, y compris la maladie d'Alzheimer, la SLA et l'atrophie multisystémique. La discussion informelle sera accessible via un webinaire en direct sur la page Événements du site internet de l'entreprise et restera disponible pendant au moins 30 jours après l'événement.
ProMIS Neurosciences (Nasdaq: PMN), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der bevorstehenden Guggenheim Securities SMID Cap Biotech Conference bekannt gegeben. Der CEO des Unternehmens, Neil Warma, wird am mittwoch, den 5. Februar 2025, um 13:30 Uhr ET in New York an einem informellen Gespräch teilnehmen.
ProMIS ist auf die Entwicklung von Antikörpertherapien spezialisiert, die auf toxische fehlgefaltete Proteine bei neurodegenerativen Erkrankungen wie der Alzheimer-Krankheit, ALS und multipler Systematrophie abzielen. Das informelle Gespräch wird über einen Live-Webcast auf der Veranstaltungsseite der Unternehmenswebsite zugänglich sein und wird mindestens 30 Tage nach der Veranstaltung verfügbar bleiben.
- None.
- None.
CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:30 p.m. ET in New York, NY.
A live webcast of the fireside chat may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company’s lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic Aβ oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to be the only antibody to selectively bind oligomers, which is expected to support better safety and efficacy. PMN 310 has successfully completed a Phase 1a clinical study and initiated a Phase 1b clinical trial in AD patients. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.
For further information:
Visit us at www.promisneurosciences.com.
Please submit media inquiries to info@promisneurosciences.com.
For Investor Relations, please contact:
Precision AQ (formerly Stern IR)
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200
FAQ
When is ProMIS Neurosciences (PMN) presenting at the Guggenheim Securities SMID Cap Biotech Conference 2025?
What diseases does ProMIS Neurosciences (PMN) focus on treating?
How can investors access ProMIS Neurosciences' (PMN) presentation at the Guggenheim Conference?
What is the main technology focus of ProMIS Neurosciences (PMN)?
